Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders

Nicoletta Cera,1,2 Stefania Bifolchetti,1,3 Giovanni Martinotti,1,2 Francesco Gambi,1,2 Gianna Sepede,1,2 Marco Onofrj,1,3 Massimo Di Giannantonio,1 Astrid Thomas1,31Department of Neuroscience and Imaging, “G. d'Annunzio” University, Chieti, Italy; 2ITAB-Institute for Ad...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cera N, Bifolchetti S, Martinotti G, Gambi F, Sepede G, Onofrj M, Di Giannantonio M, Thomas A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://doaj.org/article/d47b930d8f694c29ae878b3de2beb310
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d47b930d8f694c29ae878b3de2beb310
record_format dspace
spelling oai:doaj.org-article:d47b930d8f694c29ae878b3de2beb3102021-12-02T06:16:53ZAmantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders1178-2021https://doaj.org/article/d47b930d8f694c29ae878b3de2beb3102014-06-01T00:00:00Zhttp://www.dovepress.com/amantadine-and-cognitive-flexibility-decision-making-in-parkinson39s-p-a17226https://doaj.org/toc/1178-2021 Nicoletta Cera,1,2 Stefania Bifolchetti,1,3 Giovanni Martinotti,1,2 Francesco Gambi,1,2 Gianna Sepede,1,2 Marco Onofrj,1,3 Massimo Di Giannantonio,1 Astrid Thomas1,31Department of Neuroscience and Imaging, “G. d'Annunzio” University, Chieti, Italy; 2ITAB-Institute for Advanced Biomedical Technologies, Chieti, Italy; 3Aging Research Centre, Ce.S.I., “G. d'Annunzio” University Foundation, Chieti, ItalyIntroduction: Dopamine replacement therapy for Parkinson's disease (PD) was recently linked to the development of impulse control disorders such as pathological gambling (PG), hypersexuality, compulsive shopping, and binge or compulsive eating. Antiglutamatergic agents including amantadine (Ama) reduce these behaviors in PD and non-PD patients. The aim of our study is to evaluate the changes in executive functions, emotions, and reward/loss processing during Ama treatment in PD patients.Methods: Thirty-three patients affected by idiopathic PD were selected from a cohort of 1,096 PD patients and categorized in three different groups: ten affected by PG (PD-PG); nine PD patients with other impulse control disorder (PD-ICD); and 14 PD patient without any psychiatric disorder (PD-CTR-controls). For the neuropsychological evaluation, the following behavioral tasks where administered: the Stroop, the emotional Stroop, and the monetary reward/loss risk-taking tasks.Results: During Ama treatment, PD-PGs showed a decrease in risky choices and an increase in non-risky choices (t(9)=−2.40, P<0.05 and t(9)=2,67, P<0.05 uncorrected, respectively). Between-group comparison showed a significant decrease in risky choices for PD-PG with respect to PD-CTR (t(22)=−4.16, P<0.01), and a decreased accuracy for positive words in comparison between PD-PG and PD-ICD (t(17)=−7,49, P<0.01) and PD-PG and PD-CTR (t(22)=−4.29, P<0.01). No within- and between-group differences were observed for Stroop task.Discussion: Our data showed that Ama add-on therapy reduces hypersensitivity to reward and sustains activation toward uncertainty in PD-PG patients. These finding might explain the behavioral mechanism underlying the effect of antiglutamatergic drugs.Keywords: Parkinson’s disease, executive functions, emotion Cera NBifolchetti SMartinotti GGambi FSepede GOnofrj MDi Giannantonio MThomas ADove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1093-1101 (2014)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Cera N
Bifolchetti S
Martinotti G
Gambi F
Sepede G
Onofrj M
Di Giannantonio M
Thomas A
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
description Nicoletta Cera,1,2 Stefania Bifolchetti,1,3 Giovanni Martinotti,1,2 Francesco Gambi,1,2 Gianna Sepede,1,2 Marco Onofrj,1,3 Massimo Di Giannantonio,1 Astrid Thomas1,31Department of Neuroscience and Imaging, “G. d'Annunzio” University, Chieti, Italy; 2ITAB-Institute for Advanced Biomedical Technologies, Chieti, Italy; 3Aging Research Centre, Ce.S.I., “G. d'Annunzio” University Foundation, Chieti, ItalyIntroduction: Dopamine replacement therapy for Parkinson's disease (PD) was recently linked to the development of impulse control disorders such as pathological gambling (PG), hypersexuality, compulsive shopping, and binge or compulsive eating. Antiglutamatergic agents including amantadine (Ama) reduce these behaviors in PD and non-PD patients. The aim of our study is to evaluate the changes in executive functions, emotions, and reward/loss processing during Ama treatment in PD patients.Methods: Thirty-three patients affected by idiopathic PD were selected from a cohort of 1,096 PD patients and categorized in three different groups: ten affected by PG (PD-PG); nine PD patients with other impulse control disorder (PD-ICD); and 14 PD patient without any psychiatric disorder (PD-CTR-controls). For the neuropsychological evaluation, the following behavioral tasks where administered: the Stroop, the emotional Stroop, and the monetary reward/loss risk-taking tasks.Results: During Ama treatment, PD-PGs showed a decrease in risky choices and an increase in non-risky choices (t(9)=−2.40, P<0.05 and t(9)=2,67, P<0.05 uncorrected, respectively). Between-group comparison showed a significant decrease in risky choices for PD-PG with respect to PD-CTR (t(22)=−4.16, P<0.01), and a decreased accuracy for positive words in comparison between PD-PG and PD-ICD (t(17)=−7,49, P<0.01) and PD-PG and PD-CTR (t(22)=−4.29, P<0.01). No within- and between-group differences were observed for Stroop task.Discussion: Our data showed that Ama add-on therapy reduces hypersensitivity to reward and sustains activation toward uncertainty in PD-PG patients. These finding might explain the behavioral mechanism underlying the effect of antiglutamatergic drugs.Keywords: Parkinson’s disease, executive functions, emotion 
format article
author Cera N
Bifolchetti S
Martinotti G
Gambi F
Sepede G
Onofrj M
Di Giannantonio M
Thomas A
author_facet Cera N
Bifolchetti S
Martinotti G
Gambi F
Sepede G
Onofrj M
Di Giannantonio M
Thomas A
author_sort Cera N
title Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
title_short Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
title_full Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
title_fullStr Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
title_full_unstemmed Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
title_sort amantadine and cognitive flexibility: decision making in parkinson's patients with severe pathological gambling and other impulse control disorders
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/d47b930d8f694c29ae878b3de2beb310
work_keys_str_mv AT ceran amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
AT bifolchettis amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
AT martinottig amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
AT gambif amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
AT sepedeg amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
AT onofrjm amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
AT digiannantoniom amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
AT thomasa amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders
_version_ 1718400019745210368